<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-OV45FP1B/1060eec7-fc35-41e3-84f4-4535c12e29a1/PDF"><dcterms:extent>752 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-OV45FP1B/e608cdcc-f510-4d63-8445-f44045a0c31a/TEXT"><dcterms:extent>34 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-OV45FP1B"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2022</dcterms:issued><dc:creator>Bratkovič, Tomaž</dc:creator><dc:format xml:lang="sl">številka:2</dc:format><dc:format xml:lang="sl">letnik:73</dc:format><dc:format xml:lang="sl">str. 107-114</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID_HOST:108481539</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-OV45FP1B</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">CGRP</dc:subject><dc:subject xml:lang="sl">Klinične raziskave</dc:subject><dc:subject xml:lang="sl">Migrena</dc:subject><dc:subject xml:lang="sl">monoklonsko protitelo</dc:subject><dc:subject xml:lang="sl">Nevropatije</dc:subject><dc:subject xml:lang="sl">učinkovitost</dc:subject><dc:subject xml:lang="sl">varnost</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Monoklonska protitelesa za preprečevanje migrene| Monoclonal antibodies for the prevention of migraine|</dc:title><dc:description xml:lang="sl">Migraine is a common neurovascular disorder that can severely affect patients’ ability to perform everyday activities, thus posing tremendous disease burden for the affected patients as well as economic burden for the society. Calcitonin gene-related peptide (CGRP), a neuropeptide with vasodilatory and pronociceptive activity, is considered the main neuromodulator involved in migraine pathophysiology. Four therapeutic monoclonal antibodies targeting either CGRP or its cognate receptor constitute a new specific prophylactic antimigraine drug group, displaying favourable efficacy and safety profiles. In addition, due to long biological half-life, monoclonal antibodies require less frequent dosing compared to conventional synthetic antimigraine drugs. here, we review the representative clinical trials and discuss the properties of therapeutic antiCGRP/CGRP-receptor antibodies</dc:description><dc:description xml:lang="sl">Migrena je pogosta nevrovaskularna motnja, ki močno omeji bolnikovo sposobnost opravljanja vsakodnevnih aktivnosti in zato predstavlja precejšnje zdravstveno in psihološko breme za bolnika kot tudi ekonomsko breme za družbo. Osrednji nevromodulator, vpleten v patofiziologijo migrene, je peptid, povezan z genom za kalcitonin (CGRP), ki izkazuje vazodilatorne in nociceptivne učinke. Novo skupino specifičnih zdravilnih učinkovin za preprečevanje migrene predstavljajo štiri terapevtska monoklonska protitelesa, ki vežejo bodisi CGRP ali pripadajoč receptor. Izkazujejo dobro učinkovitost in varnost, poleg tega pa jih zaradi dolge biološke razpolovne dobe apliciramo manj pogosto kot običajna sintezna protimigrenska zdravila. V prispevku predstavljamo pregled reprezentativnih kliničnih raziskav in lastnosti terapevtskih protiteles, usmerjenih proti CGRP in njegovemu receptorju</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-OV45FP1B"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-OV45FP1B" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-OV45FP1B/1060eec7-fc35-41e3-84f4-4535c12e29a1/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-OV45FP1B/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-OV45FP1B" /></ore:Aggregation></rdf:RDF>